摘要
目的对ＬＡＫ细胞治疗慢性肝炎作客观估价．方法治疗与对照组均口服维生素，肌注肝炎灵．治疗Ａ组加回输自体ＬＡＫ细胞，每周２次，６周为１个疗程；Ｂ组每周输注异体ＬＡＫ细胞悬液１次，５次为１疗程．结果ＬＡＫ细胞治疗慢性肝炎能使部分患者ＨＢｅＡｇ及ＨＢＶＤＮＡ阴转．治疗结束时ＨＢｅＡｇ阴转率Ａ组为４７５％，Ｂ组为５８０％；而对照组Ｃ为１５０％（Ｐ＜００５）．ＨＢＶＤＮＡ阴转率Ａ组为４５０％，Ｂ组为６６０％，而对照组Ｃ为１１８％，（Ｐ＜００５％）．结论ＬＡＫ细胞治疗对ＨＢＶ复制有明显抑制作用．异体ＬＡＫ组的ＨＢｅＡｇ及ＨＢＶＤＮＡ阴转率高于自体ＬＡＫ组．
AIM To evaluate the effects of lymphokine activated killer cells (LAK) in the treatment of patients with chronic active hepatitis (CAH). METHODS All the patients in three groups (A, B, treatment groups; C, control group) were treated with oral vitamins and Ganyanling injections. In group A, auto LAK cell infusion and, in group B, allo LAK cell infusion were added respectively. RESULTS The HBeAg negative conversion rate was higher in treatment groups than in the control group, and in group A it was 47 5%, in group B, 58 0%, in group C, 15 0% ( P <0 05). The ratios of HBV DNA transverse to negative in the three groups were 45 0%, 66 0% and 11 8%, respectively. CONCLUSION LAK cells can inhibit HBV replication obviously.
关键词
病毒性肝炎
LAK细胞
杀伤细胞
治疗
Hepatitis,chronic active/therapy\ \ Lymphokine_activiated killer cells Immunotherapy\ \ DNA, viral/analysis HBeAg/analysis
